Karus Therapeutics features in BioCentury Innovations

Oxford, UK, 4 November 2016 – Karus Therapeutics, a leader in the design and development of innovative cancer therapeutics, was featured in BioCentury Innovations, ‘One Plus One Equals Four’. Chief Scientific Officer Stephen Shuttleworth details how lead program KA2237 can suppress tumor growth and metastasis directly, while dialing down PD-L1 and Tregs via different mechanisms to indirectly induce antitumor immune responses.

BioCentury Innovations: One Plus One Equals Four – November 2016